• Top
  • Medical
  • Production of Tumor-Specific Monoclonal Antibodies

Production of Tumor-Specific Monoclonal Antibodies


update:2020/06/16
NEXT
PREV
Features and Uniqueness
  • Podoplanin (PDPN/Aggrus/T1α), a platelet aggregation-inducing mucin-like sialoglycoprotein, is highly expressed in many cancers and normal tissues. A neutralizing monoclonal antibody (mAb; NZ-1) can block the association between podoplanin and C-type lectin-like receptor-2 (CLEC-2) and inhibit podoplanin-induced cancer metastasis, but NZ-1 reacts with podoplanin-expressing normal cells such as lymphatic endothelial cells. Recently, we established a platform to produce cancer-specific mAbs (CasMabs). The newly established LpMab-2 mAb reacted with podoplanin-expressing cancer cells but not with normal cells, as shown by flow cytometry and immunohistochemistry; therefore, LpMab-2 is an anti-podoplanin CasMab that is expected to be useful for molecular targeting therapy against podoplanin-expressing cancers.
Practical Application

We can produce cancer-specific mAbs (CasMabs) against all membranous proteins. CasMabs are expected to be useful for molecular targeting therapy without side effects.

Keywords

Researchers

Graduate School of Medicine

Yukinari Kato, Professor
M.D.,PhD

YouTube channel
https://www.youtube.com/@Kato-Y/videos